| Literature DB >> 28641545 |
Jin Bo Su1,2.
Abstract
NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: AT1 receptor blockers; Angiotensin-converting enzyme inhibitors; angiotensin-(1-7); bradykinin; dihydropyridine calcium channelzzm321990blockers; endothelial nitric oxide synthase; nitric oxide; statins; transcriptional and posttranscriptional regulation.
Mesh:
Substances:
Year: 2017 PMID: 28641545 DOI: 10.2174/1381612823666170622112253
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116